EcoDrugPlus

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSPKIG00000000888
Gene Symbol: CHRNA3
3 Cross references
201 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSPKIG00000012089
Gene Symbol: CHRNA4
1 Cross references
191 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSPKIG00000002510
Gene Symbol: CHRNB2
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSPKIG00000023534
Gene Symbol: CHRNB2
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSPKIG00000015370
Gene Symbol: CHRNB4
2 Cross references
191 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSPKIG00000018365
Gene Symbol: F2R
4 Cross references
154 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSPKIG00000015079
Gene Symbol: F3
4 Cross references
241 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSPKIG00000009762
Gene Symbol: LOC111855729
3 Cross references
78 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSPKIG00000000686
Gene Symbol: CCDC6
3 Cross references
218 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSPKIG00000006205
Gene Symbol: LOC111860877
2 Cross references
306 Possible Orthologues:

Complement Factor D-Like

Ensembl ID : ENSPKIG00000024495
Gene Symbol: LOC111860508
3 Cross references
133 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSPKIG00000018452
Gene Symbol: CRHR1
1 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).